Publications by authors named "Chunhan Tang"
Background: Inflammation and immune evasion are associated with tumorigenesis and progression. The Systemic Inflammation Response Index (SIRI) has been proposed as a pre-treatment peripheral blood biomarker. This study aims to compare the relationship between SIRI, various serum biomarkers, and the prognosis of NSCLC patients before and after treatment.
View Article and Find Full Text PDFObjective: Apurinic endonuclease 1 (APE1) has been suggested as an oncogene of lung tumours and our bioinformatics analysis identified the association between Erlotinib resistance and interleukin-6 (IL-6). Thus, we performed this work to delineate the mechanistic actions of APE1/IL-6 signalling in Erlotinib resistance of non-small cell lung cancer (NSCLC).
Methods: We selected human NSCLC cell lines HCC827 and PC9 to establish Erlotinib-resistant HCC827R and PC9R cells.
SOX2 is related to drug resistance in many types of cancer, including lung cancer. Herein, we investigated the role of SOX2 and its regulatory signaling in cisplatin-treated non-small-cell lung cancer (NSCLC). The effects of SOX2 on cell viability, proliferation, and apoptosis were evaluated in vitro.
View Article and Find Full Text PDFArticle Synopsis
- Pulmonary carcinosarcoma (PC) is a rare and aggressive form of non-small cell lung cancer that typically doesn’t respond well to conventional treatments like chemotherapy and radiotherapy, resulting in a poor prognosis.
- A case study was conducted on an 88-year-old patient with PC that was deemed inoperable and had a prior history of cerebral infarction.
- The patient was treated with a combination of anlotinib (a targeted therapy) and stereotactic body radiation therapy (SBRT), showing a sustained positive response for 10 months, suggesting this combo could be a promising option for older patients with PC.
To explore the clinical utility of the systemic immune-inflammation index (SII) for predicting the prognosis of esophageal squamous cell carcinoma (ESCC). After calculating the SII in 180 patients with ESCC, the relationship between SII values and the pre-/post-radiotherapy SII ratio and overall survival was determined. The median overall survival was 649 days for the entire group and 909 and 466 days for the high and low pre-/post-radiotherapy SII ratio groups, respectively.
View Article and Find Full Text PDF